In an Arthritis & Rheumatology analysis of data on 60,980 US adults with autoimmune rheumatic conditions who developed COVID-19 between December 2020 and August 2024, those who received booster or updated (2023-2024) COVID-19 vaccines were less likely to be hospitalized for COVID-19 compared to those who received only the initial series vaccines or who were unvaccinated.
Compared with no vaccination, completion of the initial series, booster vaccination, and updated vaccination were associated with 41%, 71%, and 69% lower adjusted odds of COVID-19-related hospitalization, respectively. Among patients who had received only the initial vaccine series versus booster/updated vaccine, the absolute risk reduction was 5.6%.
“Our findings provide important real-world evidence that updated vaccines continue to offer substantial protection in this medically vulnerable population,” said corresponding author Maria I. Danila, MD, MSc, MSPH, of the University of Alabama at Birmingham. “These results underscore the need for continued efforts by clinicians, policymakers, and patient advocacy groups to help ensure that these patients remain current with updated COVID-19 vaccines,” added first author Lesley E. Jackson, MD, MSPH, also of the University of Alabama at Birmingham.
URL upon publication: https://onlinelibrary.wiley.com/doi/10.1002/art.70290
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com .
About the Journal
Arthritis & Rheumatology , an official journal of the American College of Rheumatology, is a peer-reviewed publication for scientists, clinicians, and others interested in the study of rheumatic disease. We publish the highest quality basic and clinical research related to rheumatic disease, encompassing a wide range of areas of investigative activity.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com . Follow us on Facebook , X , LinkedIn and Instagram .
Arthritis & Rheumatology
Updated COVID-19 Vaccines and Health Outcomes in Patients with Autoimmune Rheumatic Conditions
9-Sep-2026